Ovarian cancer: Current status and strategies for improving therapeutic outcomes

Ashwin Chandra, Cima Pius, Madiha Nabeel, Maya Nair, Jamboor K Vishwanatha, Sarfraz Ahmad, Riyaz Basha, Ashwin Chandra, Cima Pius, Madiha Nabeel, Maya Nair, Jamboor K Vishwanatha, Sarfraz Ahmad, Riyaz Basha

Abstract

Of all the gynecologic tumors, ovarian cancer (OC) is known to be the deadliest. Advanced-stages of OC are linked with high morbidity and low survival rates despite the immense amount of research in the field. Shortage of promising screening tools for early-stage detection is one of the major challenges linked with the poor survival rate for patients with OC. In OC, therapeutic management is used with multidisciplinary approaches that includes debulking surgery, chemotherapy, and (rarely) radiotherapy. Recently, there is an increasing interest in using immunomodulation for treating OC. Relapse rates are high in this malignancy and averages around every 2-years. Further treatments after the relapse are more intense, increasing the toxicity, resistance to chemotherapy drugs, and financial burden to patients with poor quality-of-life. A procedure that has been studied to help reduce the morbidity rate involves pre-sensitizing cancer cells with standard therapy in order to produce optimal results with minimum dosage. Utilizing such an approach, platinum-based agents are effective due to their increased response to platinum-based chemotherapy in relapsed cases. These chemo-drugs also help address the issue of drug resistance. After conducting an extensive search with available literature and the resources for clinical trials, information is precisely documented on current research, biomarkers, options for treatment and clinical trials. Several schemes for enhancing the therapeutic responses for OC are discussed systematically in this review with an attempt in summarizing the recent developments in this exciting field of translational/clinical research.

Keywords: biomarkers; clinical trials; ovarian cancer; ovarian cancer screening.

Conflict of interest statement

None declared.

© 2019 The Authors. Cancer Medicine published by John Wiley & Sons Ltd.

Figures

Figure 1
Figure 1
Association of Sp transcription factors in anti‐cancer activity. Small molecules like tolfenamic acid (TA), Mithramycin A are shown to inhibit specificity protein (Sp) family of transcription factors and will result in increased apoptosis of cancer cells
Figure 2
Figure 2
Dug resistance mechanisms: A schematic representation of proteins involved in drug resistance mechanism of commonly used chemotherapeutic agents for ovarian cancer chemotherapy. The classical multiple drug resistance produced by ABC transporters and non‐ABC transporters are illustrated
Figure 3
Figure 3
Emerging immunotherapies for ovarian cancer. A schematic representation with the details on cancer vaccines, dendritic cell vaccines, adoptive T‐cell transfer, immunostimulatory cytokines are some of the techniques explained in this review
Figure 4
Figure 4
Current strategies for improving therapeutic response. Effective Targeted therapy, Usage of PARP inhibitors, combination therapy, immunotherapy, and usage of chemosensitizers are some of the future strategies for improved therapeutic responses for ovarian cancer treatment

References

    1. DeSantis CE, Miller KD, Dale W, et al. Cancer statistics for adults aged 85 years and older. CA Cancer J Clin. 2019. 10.3322/caac.21577
    1. Oronsky B, Ray CM, Spira AI, Trepel JB, Carter CA, Cottrill HM. A brief review of the management of platinum‐resistant–platinum‐refractory ovarian cancer. Med Oncol. 2017;34(6):103.
    1. Bast RC Jr, Hennessy B, Mills GB. The biology of ovarian cancer: new opportunities for translation. Nat Rev Cancer. 2009;9(6):415‐428.
    1. Wang X, Wang E, Kavanagh JJ, Freedman RS. Ovarian cancer, the coagulation pathway, and inflammation. J Transl Med. 2005;3:25.
    1. Holmes CE, Levis JE, Ornstein DL. Activated platelets enhance ovarian cancer cell invasion in a cellular model of metastasis. Clin Exp Metas. 2009;26(7):653‐661.
    1. Cheng W, Liu J, Yoshida H, Rosen D, Naora H. Lineage infidelity of epithelial ovarian cancers is controlled by HOX genes that specify regional identity in the reproductive tract. Nat Med. 2005;11(5):531‐537.
    1. Bosse K, Rhiem K, Wappenschmidt B, et al. Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: a prospective cohort study. Gynecol Oncol. 2006;103(3):1077‐1082.
    1. Olivier RI, Lubsen‐Brandsma MA, Verhoef S, van Beurden M. CA125 and transvaginal ultrasound monitoring in high‐risk women cannot prevent the diagnosis of advanced ovarian cancer. Gynecol Oncol. 2006;100(1):20‐26.
    1. Yurkovetsky ZR, Linkov FY, E Malehorn D, Lokshin AE. Multiple biomarker panels for early detection of ovarian cancer. Future Oncol. 2006;2(6):733‐741.
    1. Bandiera E, Zanotti L, Fabricio AS, et al. Cancer antigen 125, human epididymis 4, kallikrein 6, osteopontin and soluble mesothelin‐related peptide immunocomplexed with immunoglobulin M in epithelial ovarian cancer diagnosis. Clin Chem Lab Med. 2013;51(9):1815‐1824.
    1. Moro F, Pasciuto T, Djokovic D, et al. Role of CA125/CEA ratio and ultrasound parameters in identifying metastases to the ovaries in patients with multilocular and multilocular‐solid ovarian masses. Ultrasound Obstet Gynecol. 2019;53:116‐123.
    1. van Nagell JR Jr., DePriest PD, Ueland FR, et al. Ovarian cancer screening with annual transvaginal sonography: findings of 25,000 women screened. Cancer. 2007;109(9):1887‐1896.
    1. Prorok PC, Andriole GL, Bresalier RS, et al. Design of the prostate, lung, colorectal and ovarian (PLCO) cancer screening trial. Control Clin Trials. 2000;21(6 Suppl):273s‐309s.
    1. Shewell LK, Wang JJ, Paton JC, Paton AW, Day CJ, Jennings MP. Detection of N‐glycolylneuraminic acid biomarkers in sera from patients with ovarian cancer using an engineered N‐glycolylneuraminic acid‐specific lectin SubB2M. Biochem Biophys Res Commun. 2018;507(1–4):173‐177.
    1. Clarke‐Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med. 2009;361(2):170‐177.
    1. Shah CA, Lowe KA, Paley P, et al. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125, Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive. Oncology. 2009;18(5):1365‐1372.
    1. Creaney J, van Bruggen I, Hof M, et al. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma. Chest. 2007;132(4):1239‐1246.
    1. Hassan R, Remaley AT, Sampson ML, et al. Detection and quantitation of serum mesothelin, a tumor marker for patients with mesothelioma and ovarian cancer. Clin Cancer Res. 2006;12(2):447‐453.
    1. Yen MJ, Hsu CY, Mao TL, et al. Diffuse mesothelin expression correlates with prolonged patient survival in ovarian serous carcinoma. Clin Cancer Res. 2006;12(3 Pt 1):827‐831.
    1. Grossman DC, Curry SJ, Owens DK, et al. Screening for ovarian cancer: US Preventive Services Task Force recommendation statement. JAMA. 2018;319(6):588‐594.
    1. Ng CS, Zhang Z, Lee SI, et al. CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study. Clin Cancer Res. 2017;23(14):3684‐3691.
    1. Tewari D, Java JJ, Salani R, et al. Long‐term survival advantage and prognostic factors associated with intraperitoneal chemotherapy treatment in advanced ovarian cancer: a gynecologic oncology group study. J Clin Oncol. 2015;33(13):1460‐1466.
    1. Jaaback K, Johnson N, Lawrie TA. Intraperitoneal chemotherapy for the initial management of primary epithelial ovarian cancer. Cochrane Database Syst Rev. 2016;(1):Cd005340.
    1. Wright AA, Cronin A, Milne DE, et al. Use and effectiveness of intraperitoneal chemotherapy for treatment of ovarian cancer. J Clin Oncol. 2015;33(26):2841‐2847.
    1. Tanner EJ, Black DR, Zivanovic O, et al. Patterns of first recurrence following adjuvant intraperitoneal chemotherapy for stage IIIC ovarian cancer. Gynecol Oncol. 2012;124(1):59‐62.
    1. Provencher DM, Gallagher CJ, Parulekar WR, et al. OV21/PETROC: a randomized Gynecologic Cancer Intergroup phase II study of intraperitoneal versus intravenous chemotherapy following neoadjuvant chemotherapy and optimal debulking surgery in epithelial ovarian cancer. Ann Oncol. 2018;29(2):431‐438.
    1. Parmar MK, Ledermann JA, Colombo N, et al. Paclitaxel plus platinum‐based chemotherapy versus conventional platinum‐based chemotherapy in women with relapsed ovarian cancer: the ICON4/AGO‐OVAR‐2.2 trial. Lancet. 2003;361(9375):2099‐2106.
    1. Hogberg T, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in ovarian cancer. Acta Oncol. 2001;40(2–3):340‐360.
    1. Aabo K, Adams M, Adnitt P, et al. Chemotherapy in advanced ovarian cancer: four systematic meta‐analyses of individual patient data from 37 randomized trials. Advanced Ovarian Cancer Trialists' Group. Br J Cancer. 1998;78(11):1479‐1487.
    1. Neijt JP, Engelholm SA, Tuxen MK, et al. Exploratory phase III study of paclitaxel and cisplatin versus paclitaxel and carboplatin in advanced ovarian cancer. J Clin Oncol. 2000;18(17):3084‐3092.
    1. Pfisterer J, Plante M, Vergote I, et al. Gemcitabine plus carboplatin compared with carboplatin in patients with platinum‐sensitive recurrent ovarian cancer: an intergroup trial of the AGO‐OVAR, the NCIC CTG, and the EORTC GCG. J Clin Oncol. 2006;24(29):4699‐4707.
    1. Sehouli J, Camara O, Schmidt M, et al. Pegylated liposomal doxorubicin (CAELYX) in patients with advanced ovarian cancer: results of a German multicenter observational study. Cancer Chemother Pharmacol. 2009;64(3):585‐591.
    1. Ferrandina G, Ludovisi M, Lorusso D, et al. Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. J Clin Oncol. 2008;26(6):890‐896.
    1. Thiery JP. Epithelial‐mesenchymal transitions in tumour progression. Nat Rev Cancer. 2002;2(6):442‐454.
    1. Witham J, Valenti MR, De‐Haven‐Brandon AK, et al. The Bcl‐2/Bcl‐XL family inhibitor ABT‐737 sensitizes ovarian cancer cells to carboplatin. Clin Cancer Res. 2007;13(23):7191‐7198.
    1. Eliopoulos AG, Kerr DJ, Herod J, et al. The control of apoptosis and drug resistance in ovarian cancer: influence of p53 and Bcl‐2. Oncogene. 1995;11(7):1217‐1228.
    1. Adams JM, Cory S. The Bcl‐2 apoptotic switch in cancer development and therapy. Oncogene. 2007;26(9):1324‐1337.
    1. Vogler M. BCL2A1: the underdog in the BCL2 family. Cell Death Differ. 2012;19(1):67‐74.
    1. Wang H, Zhang Z, Wei X, Dai R. Small‐molecule inhibitor of Bcl‐2 (TW‐37) suppresses growth and enhances cisplatin‐induced apoptosis in ovarian cancer cells. J Ovarian Res. 2015;8:3.
    1. Zeitlin BD, Zeitlin IJ, Nor JE. Expanding circle of inhibition: small‐molecule inhibitors of Bcl‐2 as anticancer cell and antiangiogenic agents. J Clin Oncol. 2008;26(25):4180‐4188.
    1. Yamamoto T, Tanigawa N. The role of survivin as a new target of diagnosis and treatment in human cancer. Med Electron Microsc. 2001;34(4):207‐212.
    1. Lengyel E, Prechtel D, Resau JH, et al. C‐Met overexpression in node‐positive breast cancer identifies patients with poor clinical outcome independent of Her2/neu. Int J Cancer. 2005;113(4):678‐682.
    1. Jagadeeswaran R, Ma PC, Seiwert TY, et al. Functional analysis of c‐Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. Can Res. 2006;66(1):352‐361.
    1. Kong DS, Song SY, Kim DH, et al. Prognostic significance of c‐Met expression in glioblastomas. Cancer. 2009;115(1):140‐148.
    1. Di Renzo MF, Olivero M, Katsaros D, et al. Overexpression of the Met/HGF receptor in ovarian cancer. Int J Cancer. 1994;58(5):658‐662.
    1. Gherardi E, Birchmeier W, Birchmeier C, Vande Woude G. Targeting MET in cancer: rationale and progress. Nat Rev Cancer. 2012;12(2):89‐103.
    1. Birchmeier C, Birchmeier W, Gherardi E, Vande Woude GF. Met, metastasis, motility and more. Nat Rev Mol Cell Biol. 2003;4(12):915‐925.
    1. Appleman LJ. MET signaling pathway: a rational target for cancer therapy. J Clin Oncol. 2011;29(36):4837‐4838.
    1. De Bacco F, Luraghi P, Medico E, et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J Natl Cancer Inst. 2011;103(8):645‐661.
    1. Kim HJ, Yoon A, Ryu JY, et al. c‐MET as a potential therapeutic target in ovarian clear cell carcinoma. Sci Rep. 2016;6:38502.
    1. Safe S, Abdelrahim M. Sp transcription factor family and its role in cancer. Eur J Cancer. 2005;41(16):2438–2448.
    1. Johnson SW, Laub PB, Beesley JS, Ozols RF, Hamilton TC. Increased platinum‐DNA damage tolerance is associated with cisplatin resistance and cross‐resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Can Res. 1997;57(5):850‐856.
    1. Stavrovskaya AA. Cellular mechanisms of multidrug resistance of tumor cells. Biochemistry. 2000;65(1):95‐106.
    1. Kruh GD, Belinsky MG. The MRP family of drug efflux pumps. Oncogene. 2003;22(47):7537‐7552.
    1. Surowiak P, Materna V, Denkert C, et al. Significance of cyclooxygenase 2 and MDR1/P‐glycoprotein coexpression in ovarian cancers. Cancer Lett. 2006;235(2):272‐280.
    1. Januchowski R, Sterzynska K, Zaorska K, et al. Analysis of MDR genes expression and cross‐resistance in eight drug resistant ovarian cancer cell lines. J Ovarian Res. 2016;9(1):65.
    1. Leonard GD, Fojo T, Bates SE. The role of ABC transporters in clinical practice. Oncologist. 2003;8(5):411‐424.
    1. Cole SP, Bhardwaj G, Gerlach JH, et al. Overexpression of a transporter gene in a multidrug‐resistant human lung cancer cell line. Science. 1992;258(5088):1650‐1654.
    1. Sodani K, Patel A, Kathawala RJ, Chen ZS. Multidrug resistance associated proteins in multidrug resistance. Chin J Cancer. 2012;31(2):58‐72.
    1. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci USA. 2002;99(22):14298‐14302.
    1. Holzer AK, Manorek GH, Howell SB. Contribution of the major copper influx transporter CTR1 to the cellular accumulation of cisplatin, carboplatin, and oxaliplatin. Mol Pharmacol. 2006;70(4):1390‐1394.
    1. Howell SB, Safaei R, Larson CA, Sailor MJ. Copper transporters and the cellular pharmacology of the platinum‐containing cancer drugs. Mol Pharmacol. 2010;77(6):887‐894.
    1. Kilari D, Guancial E, Kim ES. Role of copper transporters in platinum resistance. World J Clin Oncol. 2016;7(1):106‐113.
    1. Sharma SV, Lee DY, Li B, et al. A chromatin‐mediated reversible drug‐tolerant state in cancer cell subpopulations. Cell. 2010;141(1):69‐80.
    1. Chang X, Monitto CL, Demokan S, et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Can Res. 2010;70(7):2870‐2879.
    1. Maliepaard M, van Gastelen MA, de Jong LA, et al. Overexpression of the BCRP/MXR/ABCP gene in a topotecan‐selected ovarian tumor cell line. Can Res. 1999;59(18):4559‐4563.
    1. Zhang F, Throm SL, Murley LL, et al. MDM2 antagonist nutlin‐3a reverses mitoxantrone resistance by inhibiting breast cancer resistance protein mediated drug transport. Biochem Pharmacol. 2011;82(1):24‐34.
    1. Robey RW, Polgar O, Deeken J, To KW, Bates SE. ABCG2: determining its relevance in clinical drug resistance. Cancer Metastasis Rev. 2007;26(1):39‐57.
    1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell. 2000;100(1):57‐70.
    1. Kalluri R, Neilson EG. Epithelial‐mesenchymal transition and its implications for fibrosis. J Clin Investig. 2003;112(12):1776‐1784.
    1. Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell. 2011;144(5):646‐674.
    1. Wang X, Ling MT, Guan XY, et al. Identification of a novel function of TWIST, a bHLH protein, in the development of acquired taxol resistance in human cancer cells. Oncogene. 2004;23(2):474‐482.
    1. Kajiyama H, Shibata K, Terauchi M, et al. Chemoresistance to paclitaxel induces epithelial‐mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int J Oncol. 2007;31(2):277‐283.
    1. Polyak K, Weinberg RA. Transitions between epithelial and mesenchymal states: acquisition of malignant and stem cell traits. Nat Rev Cancer. 2009;9(4):265‐273.
    1. Bagnato A, Rosano L. Understanding and overcoming chemoresistance in ovarian cancer: emerging role of the endothelin axis. Current Oncol. 2012;19(1):36‐38.
    1. Rosano L, Cianfrocca R, Spinella F, et al. Acquisition of chemoresistance and EMT phenotype is linked with activation of the endothelin A receptor pathway in ovarian carcinoma cells. Clin Cancer Res. 2011;17(8):2350‐2360.
    1. Rosano L, Spinella F, Di Castro V, et al. Endothelin‐1 promotes epithelial‐to‐mesenchymal transition in human ovarian cancer cells. Can Res. 2005;65(24):11649‐11657.
    1. Santamaria PG, Moreno‐Bueno G, Portillo F, Cano A. EMT: present and future in clinical oncology. Mol Oncol. 2017;11(7):718‐738.
    1. Jessy T. Immunity over inability: the spontaneous regression of cancer. J Nat Sci Biol Med. 2011;2(1):43‐49.
    1. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329‐360.
    1. Vesely MD, Kershaw MH, Schreiber RD, Smyth MJ. Natural innate and adaptive immunity to cancer. Annu Rev Immunol. 2011;29:235‐271.
    1. McCloskey CW, Rodriguez GM, Galpin K, Vanderhyden BC. Ovarian cancer immunotherapy: preclinical models and emerging therapeutics. Cancers. 2018;10(8):244.
    1. Rosenberg SA, Dudley ME. Adoptive cell therapy for the treatment of patients with metastatic melanoma. Curr Opin Immunol. 2009;21(2):233‐240.
    1. Lohmueller J, Finn OJ. Current modalities in cancer immunotherapy: immunomodulatory antibodies, CARs and vaccines. Pharmacol Ther. 2017;178:31‐47.
    1. Pakish JB, Jazaeri AA. Immunotherapy in gynecologic cancers: are we there yet? Curr Treat Options Oncol. 2017;18(10):59.
    1. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte‐associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci USA. 2003;100(14):8372‐8377.
    1. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti‐PD‐1 antibody in cancer. N Engl J Med. 2012;366(26):2443‐2454.
    1. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti‐PD‐L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455‐2465.
    1. Sato E, Olson SH, Ahn J, et al. Intraepithelial CD8+ tumor‐infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer. Proc Natl Acad Sci USA. 2005;102(51):18538‐18543.
    1. Barnett JC, Bean SM, Whitaker RS, et al. Ovarian cancer tumor infiltrating T‐regulatory (T(reg)) cells are associated with a metastatic phenotype. Gynecol Oncol. 2010;116(3):556‐562.
    1. Gaillard SL, Secord AA, Monk B. The role of immune checkpoint inhibition in the treatment of ovarian cancer. Gynecol Oncol Res Pract. 2016;3:11.
    1. Hartkopf AD, Fehm T, Wallwiener M, Lauer U. Oncolytic viruses to treat ovarian cancer patients—a review of results from clinical trials. Geburtshilfe Frauenheilkd. 2012;72(2):132‐136.
    1. Yigit R, Massuger LF, Figdor CG, Torensma R. Ovarian cancer creates a suppressive microenvironment to escape immune elimination. Gynecol Oncol. 2010;117(2):366‐372.
    1. Kuhn I, Bauzon M, Green N, Seymour L, Fisher K, Hermiston T. OvAd1, a novel, potent, and selective chimeric oncolytic virus developed for ovarian cancer by 3D‐directed evolution. Mol Ther Oncolytics. 2017;4:55‐66.
    1. Uusi‐Kerttula H, Davies JA, Thompson JM, et al. Ad5NULL‐A20: a tropism‐modified, alphavbeta6 Integrin‐selective oncolytic adenovirus for epithelial ovarian cancer therapies. Clin Cancer Res. 2018;24(17):4215‐4224.
    1. Ribas A, Dummer R, Puzanov I, et al. Oncolytic virotherapy promotes intratumoral T cell infiltration and improves anti‐PD‐1 immunotherapy. Cell. 2017;170(6):1109‐1119.e10.
    1. Besser MJ, Shapira‐Frommer R, Treves AJ, et al. Clinical responses in a phase II study using adoptive transfer of short‐term cultured tumor infiltration lymphocytes in metastatic melanoma patients. Clin Cancer Res. 2010;16(9):2646‐2655.
    1. Dummer R, Hoeller C, Gruter IP, Michielin O. Combining talimogene laherparepvec with immunotherapies in melanoma and other solid tumors. Cancer Immunol Immunother. 2017;66(6):683‐695.
    1. Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science. 2002;298(5594):850‐854.
    1. Freedman RS, Edwards CL, Kavanagh JJ, et al. Intraperitoneal adoptive immunotherapy of ovarian carcinoma with tumor‐infiltrating lymphocytes and low‐dose recombinant interleukin‐2: a pilot trial. J Immunother Emphasis Tumor Immunol. 1994;16(3):198‐210.
    1. Santoiemma PP, Powell DJ Jr. Tumor infiltrating lymphocytes in ovarian cancer. Cancer Biol Ther. 2015;16(6):807‐820.
    1. Power AT, Wang J, Falls TJ, et al. Carrier cell‐based delivery of an oncolytic virus circumvents antiviral immunity. Mol Ther. 2007;15(1):123‐130.
    1. Arulanandam R, Batenchuk C, Angarita FA, et al. VEGF‐mediated induction of PRD1‐BF1/Blimp1 expression sensitizes tumor vasculature to oncolytic virus infection. Cancer Cell. 2015;28(2):210‐224.
    1. Yang JC, Rosenberg SA. Adoptive T‐Cell therapy for cancer. Adv Immunol. 2016;130:279‐294.
    1. Sadelain M, Brentjens R, Riviere I. The promise and potential pitfalls of chimeric antigen receptors. Curr Opin Immunol. 2009;21(2):215‐223.
    1. Kershaw MH, Westwood JA, Parker LL, et al. A phase I study on adoptive immunotherapy using gene‐modified T cells for ovarian cancer. Clin Cancer Res. 2006;12(20 Pt 1):6106‐6115.
    1. Kandalaft LE, Powell DJ Jr, Coukos G. A phase I clinical trial of adoptive transfer of folate receptor‐alpha redirected autologous T cells for recurrent ovarian cancer. J Transl Med. 2012;10:157.
    1. Lanitis E, Dangaj D, Hagemann IS, et al. Primary human ovarian epithelial cancer cells broadly express HER2 at immunologically‐detectable levels. PLoS ONE. 2012;7(11):e49829.
    1. Chekmasova AA, Rao TD, Nikhamin Y, et al. Successful eradication of established peritoneal ovarian tumors in SCID‐Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen. Clin Cancer Res. 2010;16(14):3594‐3606.
    1. Felder M, Kapur A, Gonzalez‐Bosquet J, et al. MUC16 (CA125): tumor biomarker to cancer therapy, a work in progress. Mol Cancer. 2014;13:129.
    1. Chang K, Pastan I. Molecular cloning of mesothelin, a differentiation antigen present on mesothelium, mesotheliomas, and ovarian cancers. Proc Natl Acad Sci USA. 1996;93(1):136‐140.
    1. Yoon DH, Osborn MJ, Tolar J, Kim CJ. Incorporation of immune checkpoint blockade into chimeric antigen receptor T cells (CAR‐Ts): combination or built‐in CAR‐T. Int J Mol Sci. 2018;19(2).
    1. Pujade‐Lauraine E. New treatments in ovarian cancer. Ann Oncol. 2017;28(suppl_8):viii57‐viii60.
    1. Wiggans AJ, Cass GK, Bryant A, Lawrie TA, Morrison J. Poly(ADP‐ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer. Cochrane Database Syst Rev. 2015;(5):Cd007929.
    1. Ratner ES, Sartorelli AC, Lin ZP. Poly (ADP‐ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol. 2012;24(5):564‐571.
    1. Yellepeddi VK, Vangara KK, Kumar A, Palakurthi S. Comparative evaluation of small‐molecule chemosensitizers in reversal of cisplatin resistance in ovarian cancer cells. Anticancer Res. 2012;32(9):3651‐3658.
    1. Diab Y, Muallem MZ. Targeted therapy in ovarian cancer. A comprehensive systematic review of literature. Anticancer Res. 2017;37(6):2809‐2815.
    1. McCabe N, El-Helali A, Steele C, et al. Platinum based chemotherapy selects for PDGFRα dependent angiogenesis. J Clin Oncol. 2018;36(15_suppl):5578–5578.
    1. Cortez AJ, Tudrej P, Kujawa KA, Lisowska KM. Advances in ovarian cancer therapy. Cancer Chemother Pharmacol. 2018;81(1):17‐38.
    1. Rodriguez GM, Galpin K, McCloskey CW, Vanderhyden BC. The tumor microenvironment of epithelial ovarian cancer and its influence on response to immunotherapy. Cancers. 2018;10(8):242.

Source: PubMed

赞助者和合作者

医疗条件

药物干预

3
订阅